Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16993)	3/10/1998 12:54:00 AM
From: DrJerry	Respond to of 32384

HENRY: You sure have confused me with your misleading posts. Since Ligand already owns the rights to Evista why are they dickering over paying another measly 20mil- also, since Glaxo has merged with Warner Lambert why did they conspire to take Rezulin off the UK market? Also I don't quite get J & J bidding 150mil for srgn's drug when they decided to punt on Ergostat. Such misleading bits of information need to be censored. Anyway after reading your wait until Monday March 9th post of several weeks ago,I decided to jump in with both feet and stock up on LGNDW between 5 and 7. I am sure smiling about your picking Fugazi's "former" choice. To hell with the critics- I am forever grateful.